Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Brokerages

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has been given an average recommendation of “Moderate Buy” by the ten brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $40.5833.

Several research analysts have issued reports on the company. HC Wainwright boosted their target price on Genmab A/S from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Jefferies Financial Group initiated coverage on Genmab A/S in a research note on Tuesday, February 17th. They set a “buy” rating and a $41.50 price target for the company. Wells Fargo & Company began coverage on Genmab A/S in a report on Monday, March 2nd. They set an “overweight” rating and a $40.00 price objective for the company. Wall Street Zen downgraded Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, Guggenheim reduced their target price on Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, February 23rd.

Genmab A/S Stock Down 1.6%

Shares of GMAB opened at $26.14 on Friday. The company has a quick ratio of 2.01, a current ratio of 2.02 and a debt-to-equity ratio of 0.86. The business has a fifty day moving average of $30.94 and a 200 day moving average of $30.50. The company has a market cap of $16.79 billion, a PE ratio of 16.86, a P/E/G ratio of 1.07 and a beta of 0.94. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $35.43.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.41). Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.The firm had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. On average, sell-side analysts expect that Genmab A/S will post 1.45 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Founders Capital Management grew its stake in Genmab A/S by 40.0% in the 4th quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after acquiring an additional 400 shares in the last quarter. Parallel Advisors LLC boosted its holdings in shares of Genmab A/S by 11.3% in the third quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock valued at $127,000 after purchasing an additional 419 shares during the period. CWM LLC boosted its holdings in shares of Genmab A/S by 18.8% in the fourth quarter. CWM LLC now owns 2,739 shares of the company’s stock valued at $84,000 after purchasing an additional 433 shares during the period. Jones Financial Companies Lllp grew its stake in Genmab A/S by 29.1% in the third quarter. Jones Financial Companies Lllp now owns 1,951 shares of the company’s stock worth $57,000 after purchasing an additional 440 shares in the last quarter. Finally, Osaic Holdings Inc. grew its stake in Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.